Research analysts at Aegis assumed coverage on shares of Akebia Therapeutics Inc. (NASDAQ:AKBA) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

AKBA has been the topic of a number of other research reports. Brean Capital started coverage on Akebia Therapeutics in a report on Thursday, September 29th. They issued a “buy” rating and a $18.00 price objective on the stock. JMP Securities reiterated a “buy” rating on shares of Akebia Therapeutics in a report on Thursday, November 10th. Zacks Investment Research upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. HC Wainwright reiterated a “buy” rating on shares of Akebia Therapeutics in a report on Tuesday, August 23rd. Finally, Credit Suisse Group AG reiterated a “hold” rating and issued a $8.00 price objective on shares of Akebia Therapeutics in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $14.43.

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA) opened at 8.90 on Tuesday. The company’s 50-day moving average price is $8.30 and its 200 day moving average price is $8.38. The stock’s market capitalization is $162.87 million. Akebia Therapeutics has a 12 month low of $7.00 and a 12 month high of $13.20.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.13. During the same period in the previous year, the company posted ($0.47) earnings per share. On average, analysts forecast that Akebia Therapeutics will post ($3.47) earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Alliancebernstein L.P. acquired a new stake in Akebia Therapeutics during the second quarter valued at approximately $105,000. BlackRock Advisors LLC boosted its stake in Akebia Therapeutics by 4.3% in the second quarter. BlackRock Advisors LLC now owns 16,531 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 676 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Akebia Therapeutics during the second quarter valued at approximately $147,000. American International Group Inc. boosted its stake in Akebia Therapeutics by 44.9% in the second quarter. American International Group Inc. now owns 20,684 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 6,405 shares in the last quarter. Finally, Highbridge Capital Management LLC acquired a new stake in Akebia Therapeutics during the third quarter valued at approximately $195,000. 51.15% of the stock is owned by institutional investors and hedge funds.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

5 Day Chart for NASDAQ:AKBA

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.